Enzalutamide (Xtandi) for non-metastatic castration resistant prostate cancer

NIHRIO (HSRIC) ID: 17171  NICE ID: 9715

Prostate cancer is cancer of the prostate gland (a small organ in a man’s pelvis) and is the second most common cancer in the UK. There are three stages of prostate cancer; localised, locally-advanced and advanced prostate cancer. Non-metastatic prostate cancer is a type of localised cancer that has not spread to other parts of the body. Symptoms may not appear for many years because it develops slowly, however they can include difficulty or more frequent passing of urine, feeling of not completely emptying bladder and blood in urine or semen.

Enzalutamide (Xtandi) is a drug which blocks the effect of the hormone testosterone on the prostate and so slows down the growth of the cancer. Enzalutamide is taken as four capsules once a day. If licenced in the UK, it could provide an additional treatment option for patients with non-metastatic castration resistant prostate cancer.

This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information.

This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.
### TARGET GROUP

Castration resistant prostate cancer, non-metastatic.

### TECHNOLOGY

### DESCRIPTION

Enzalutamide (Xtandi) is a hormone therapy drug classed as a potent androgen receptor signalling inhibitor which blocks the effects of testosterone, a male hormone that cancer of the prostate depends on. It does this by targeting the androgen receptors to which the hormone attaches and prevents them from responding to natural testosterone. By blocking the action of testosterone, enzalutamide slows down the growth of the cancer.\(^1\)

In the ongoing phase III trial, enzalutamide was administered orally in capsule formulation as four 40mg capsules once daily for up to 37 weeks.\(^2\)

Enzalutamide is currently licensed in the EU for metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer.\(^3\) Recognised common adverse effects (≥10%) of enzalutamide are falls, broken bones, feeling anxious, dry skin, itching, memory problems, breast enlargement in men (gynaecomastia), symptom of restless legs syndrome (an uncontrollable urge to move a part of the body, usually the leg), reduced concentration and forgetfulness.\(^4\)

Enzalutamide is currently in phase II trials in the EU for hepatocellular carcinoma and in phase III trials in the EU for hormone refractory, castration-resistance, androgen dependant prostate cancer and hormone sensitive prostate cancer.\(^5\)

### INNOVATION and/or ADVANTAGES

If licensed, enzalutamide will offer an additional treatment option for patients with non-metastatic castration resistant prostate cancer. It is approved by the U.S. Food and Drug Administration and in Europe for the treatment of patients with metastatic castrate-resistant prostate cancer (CRPC), based on clinical studies showing statistically significant overall survival benefit versus placebo.\(^6\)

### DEVELOPER

Pfizer, and Astellas Pharma Inc

### PATIENT GROUP

### BACKGROUND

Prostate cancer is the most common male cancer in the UK. It affects the prostate gland which produces some of the fluid in the semen and plays a role in urine control in men. The cancer starts in the glandular cells in the prostate and are known as acinar adenocarcinomas. It is more common in black Caribbean and black African men than in white men and very rare in Asian men. More than half of those diagnosed are aged 70 years and over.\(^7\) There are three stages of prostate cancer; non-
metastatic or localised (confined to the prostate gland), locally-advanced (spread outside the capsule of the gland) and advanced prostate cancer (spread to other body organs).  

Non-metastatic prostate cancer is defined as cancer with no evidence of metastasis and at least one of the following three criteria: A Gleason score no higher than 6, prostate-specific antigen (PSA) level less than 10ng/ml or a local clinical stage between T1 and T2a. A Gleason score is a system of grading prostate cancer tissue based on its microscopic appearance. The scores range from 2 to 10 with a higher score indicating that it is more likely to spread. A PSA test measures the amount of PSA in the blood and a raised level can be a sign of a problem with the prostate. PSA doubling time is an important measure for disease activity and can be used to find patients who are at higher risk for adverse outcome. The clinical stage describes the size of the tumour (T) ranging from T1 (cancer is too small to be seen on a scan, or felt during examination of the prostate) to T4 (cancer has spread into other body organs).

Because the cancer develops slowly, people often have no signs in the early stages and symptoms only become apparent when the prostate is large enough to affect the urethra. General symptoms of prostate cancer include: urinary tract infection, urinary frequency, sensation of incomplete emptying, haematuria (presence of blood in urine), dysuria (painful urination), haematospermia (blood in sperm), symptoms of acute kidney injury or chronic kidney disease and impotence. Various risk factors for prostate cancer have been identified, including ageing, black ethnic origin and a family history. Other factors include diet, pattern of sexual behaviour, alcohol consumption, exposure to ultraviolet radiation, chronic inflammation and occupational exposure.

---

**CLINICAL NEED and BURDEN OF DISEASE**

For the UK, the age-standardised incidence of prostate cancer was 175 per 100,000 in 2014 and the lifetime risk of being diagnosed with prostate cancer was estimated to be 1 in 8.

For men (aged 15-99) in England and Wales diagnosed with prostate cancer, 85% will survive five years or more after diagnosis.

In 2015, there were 63,964 admissions for prostate cancer (ICD-10 C61) in England, resulting in 102,107 bed days and 68,578 finished consultant episodes. In the UK, prostate cancer is the second most common cause of cancer death, with around 11,300 deaths reported in 2014.

In 2017, the population likely to be eligible to receive enzalutamide is estimated to be around 1.19% of men aged 40 and above.

---

**PATIENT PATHWAY**

**RELEVANT GUIDANCE**

**NICE GUIDANCE**

There are several treatment options available to those with non-metastatic castration resistant prostate cancer. Many men with localised prostate cancer will not benefit from definitive treatment, and 45% of men with PSA-detected prostate cancer are candidates for deferred management (watchful waiting). In men with comorbidity and limited life expectancy, treatment of localised prostate cancer may be deferred to avoid loss of quality of life.\textsuperscript{6} Treatment recommendations are dependent on the disease and patient characteristics. Guidelines recommend the use of:\textsuperscript{13}

- Watchful waiting or observation

\textbf{NHS ENGLAND and POLICY GUIDANCE}


\textbf{OTHER GUIDANCE}


\textbf{CURRENT TREATMENT OPTIONS}
• Radical prostatectomy (surgical removal of the entire prostate gland between the urethra and bladder)
• External beam radiotherapy
• Brachytherapy (trans-perineal implantation of radioactive seeds into the prostate)
• Cryotherapy (local or general use of low temperatures in medical therapy)
• Hormone therapy (androgen deprivation or anti-androgens)

### EFFICACY and SAFETY

<table>
<thead>
<tr>
<th>Trial</th>
<th>PROSPER, NCT02003924, MDV3100-14; adult male; enzalutamide vs placebo; phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Status</td>
<td>Recruitment has stopped</td>
</tr>
<tr>
<td>Source of Information</td>
<td>Trial registry&lt;sup&gt;17&lt;/sup&gt;</td>
</tr>
<tr>
<td>Location</td>
<td>EU (incl UK), USA, South America, Asia, Australia and Oceania</td>
</tr>
<tr>
<td>Design</td>
<td>Randomized, double blind, placebo controlled study</td>
</tr>
<tr>
<td>Participants</td>
<td>N=1440 (planned); 18 years and older; males; prostate cancer; non-metastatic castration-resistant; progressing after definitive therapy; second line</td>
</tr>
<tr>
<td>Schedule</td>
<td>Randomised to placebo or enzalutamide 160 mg by mouth once daily up to 16 weeks</td>
</tr>
<tr>
<td>Follow-up</td>
<td>Not reported</td>
</tr>
<tr>
<td>Primary Outcomes</td>
<td>Metastasis free survival (MFS): ≥ 16 weeks</td>
</tr>
<tr>
<td>Secondary Outcomes</td>
<td>Overall survival: ≥ 16 weeks; Time to pain progression: ≥ 16 weeks; Time to opiate use for prostate: ≥ 16 weeks; Time to first use of cytotoxic: ≥ 16 weeks; Time to first use of new antineoplastic therapy: ≥ 16 weeks; Time to prostate-specific antigen (PSA) progression: ≥ 16 weeks; FACT-P global score: ≥ 16 weeks; Quality of life as assessed by EQ-5D-5L and QLQ-PR25: ≥ 16 weeks</td>
</tr>
<tr>
<td>Key Results</td>
<td>-</td>
</tr>
<tr>
<td>Adverse effects (AEs)</td>
<td>-</td>
</tr>
<tr>
<td>Expected reporting date</td>
<td>-</td>
</tr>
</tbody>
</table>

### ESTIMATED COST and IMPACT

**COST**

Enzalutamide is already marketed individually in the UK for use before chemotherapy for men with advanced prostate cancer which is no longer responding to hormone treatment; a pack of 112 x 40mg capsules costs £2,735 and the unit cost per capsule costs £24.<sup>18</sup>
### IMPACT – SPECULATIVE

**IMPACT ON PATIENTS AND CARERS**

- Reduced mortality/increased length of survival
- Reduced symptoms or disability: a potential improvement in quality of life

- Other
- No impact identified

**IMPACT ON HEALTH and SOCIAL CARE SERVICES**

- Increased use of existing services
- Decreased use of existing services

- Re-organisation of existing services
- Need for new services

- Other
- None identified

**IMPACT ON COSTS and OTHER RESOURCE USE**

- Increased drug treatment costs
- Reduced drug treatment costs

- Other increase in costs
- Other reduction in costs

- Other: uncertain cost
- None identified

**OTHER ISSUES**

- Clinical uncertainty or other research question identified
- None identified

### REFERENCES
